AbCellera Biologics Inc.NASDAQ: ABCL

Corporate Overview November 2026

· Issued by AbCellera Biologics Inc.
AbCellera Corporate Overview

COPYRIGHT © ABCELLERA

November 10, 2026

Corporate Overview

We are a clinical-stage biotech company focused on developing novel antibody

Liquidity

We continue to maintain a strong liquidity position to execute on our strategy

Programs

We are advancing an internal pipeline of programs.

$790M+

in total cash balances & marketable securities

20+

internal program starts

$100M+

in available government funding

5

programs in IND-enabling activities

3yrs+

of funding for pipeline investments

2

molecules in the clinic1

medicines

Platform ~$1B

300K+sq ft

Founded: 2012

Employees: ~600

Locations: Vancouver & Montreal, Canada

We have built a fully integrated antibody drug platform from discovery to clinical manufacturing and development.

in total platform

investments

of research and manufacturing facilities

Sydney, Australia

Partnerships 100+

40+ 12

COPYRIGHT © ABCELLERA

IPO: December 2020

We formed partnerships with companies that bring

novel biology or technology.

partner-led programs supported

partners

molecules in the clinic2

As of September 30, 2026

As of September 30, 2026

  1. AbCellera-led programs

  2. Partner-led programs, including under Trianni licenses, understood to be progressing in the clinic.

3

100+ 12

Corporate Overview

Our platform was built through 10+ years of drug discovery partnerships

Since 2014, we have partnered with some of the industry's most innovative pharma and biotech companies. Partnerships were a driver for R&D, and provided near-term revenue in the form of

research payments and long-term potential revenue in the form of royalty stakes in those drug programs.

COPYRIGHT © ABCELLERA

In 2023, we shifted our focus from partnerships to advancing a pipeline of internal programs.

partner-led programs supported

molecules from partner-led programs are understood to be progressing in the clinic*

AbbVie

*As of September 30, 2026

4

STRATEGY

Corporate Overview

Use our competitive advantage in antibody drug creation to build a pipeline of differentiated assets

Discovery for GPCR and ion channel targets

Novel modalities, including multispecifics and ADCs

Indication agnostic

COPYRIGHT © ABCELLERA

5

ABCELLERA PIPELINE

PROGRAMS TARGET INDICATION THERAPEUTIC AREA STAGE

Corporate Overview

IND-Enabling Phase 1 Phase 2 Phase 3

ABCL635

NK3R

VMS due to menopause

Endocrinology

& Women's Health

VMS due to breast cancer treatment

Oncology

VMS due to prostate cancer treatment

Oncology

ABCL992

NK3R

VMS

Endocrinology

ABCL575

OX40L

Atopic Dermatitis

Immunology & Inflammation

ABCL688

Undisclosed

GPCR / ion channel

Undisclosed

Autoimmunity

ABCL386

Undisclosed

Undisclosed

Oncology

ABCL385

Undisclosed

Undisclosed

Oncology

ABCL646

Undisclosed

Ion channel

Undisclosed

Undisclosed

COPYRIGHT © ABCELLERA

6 As of September 30, 2026

2026 PRIORITIES

In Q3, we advanced ABCL992, ABCL385, and ABCL646 into the pipeline, completing all 2026 priorities

Corporate Overview

ABCL635 Phase 2 clinical trial

top-line readout on Aug 10, 2026

ABCL575 Phase 1 clinical trial

top-line readout on Nov 9, 2026

ABCL688 progressing through

IND-enabling activities

ABCL386 progressing through

IND-enabling activities

Nominate at least 1 additional development candidate for

IND-enabling activities

COPYRIGHT © ABCELLERA

7

Internal Programs

8

COPYRIGHT © ABCELLERA Corporate Overview

Internal Programs ABCL635

9

COPYRIGHT © ABCELLERA Corporate Overview

ABCL635

ABCL635 is an investigational potential first-in-class antibody for the non-hormonal treatment of moderate and severe vasomotor symptoms

Target

Corporate Overview

Neurokinin 3 receptor (NK3R)

Target Type

G protein-coupled receptor (GPCR)

Indication

Moderate and severe vasomotor symptoms (VMS) due to menopause

Status

Phase 2

COPYRIGHT © ABCELLERA

First GPCR-targeting antibody from our platform to advance into our internal pipeline

Additional opportunities

in oncology

10

ABCL635 Opportunity

ABCL635 could help to address a large unmet need for the treatment of VMS due to menopause and cancer treatments

VMS Due to Menopause

Corporate Overview

4+ years

is the median duration for vasomotor symptoms post final

Market Opportunity VMS Due to Menopause

1M+ women

could benefit from safe and effective non-hormonal treatments.3

VMS Due to Cancer Treatment

Many patients experience VMS during cancer treatment

menstrual period.1

Symptoms: Sudden and intense feeling of heat that leads to sweating, chills, and interrupted sleep.2

~12M women in

the US experience moderate-to-severe VMS.3

$6B+

>6M of which

seek treatment.

~20% for whom

3 hormone therapy is unsuitable due to contraindications or other factors.4

that includes hormone suppression for:

  • Breast cancer

  • Prostate cancer

  • Ovarian cancer

    COPYRIGHT © ABCELLERA

    Total Addressable Market estimated for non-hormonal treatments assuming only current small-molecule gross prices as >$5K per patient per year.5

    1. Avis et al., JAMA Intern Med., 2015.

    2. Nappi et al., Menopause, 2021.

    3. Management estimate based on US census data, 2023; Todorova et al., Menopause, 2023; Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022.

    4. Management estimate based on Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022.

    5. Management estimate based on Wholesale Acquisition Cost of Veozah and Lynkuet (accessed from Micromedex Red Book) and above sources.

11 Actual market size may differ.

ABCL635

Market Opportunity

Over 1 million women in the US are estimated to need a non-hormonal treatment for moderate and severe VMS due to menopause

Contraindicated for

MHT

Corporate Overview

MHT not tolerated

1M+

~20% in need of non-hormonal treatment2

~12M

women in the US with moderate-to-severe

VMS due to menopause1

6M+

>50% seek treatment1

<50% do not seek treatment 1

Eligible for MHT

80% successfully treated with or remaining eligible for MHT2

COPYRIGHT © ABCELLERA

  1. Management estimate based on US census data, 2023; Todorova et al., Menopause, 2023; Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022.

  2. Management estimate based on Nappi et al., Menopause, 2021; Stute et al., Maturitas, 2022. Actual market size may differ.

12

ABCL635 Science

NK3R antagonists are effective, non-hormonal options for VMS

Corporate Overview

Reproductive State

COPYRIGHT © ABCELLERA

13

ABCL635 Science

NK3R antagonists are effective, non-hormonal options for VMS

Corporate Overview

Menopause

COPYRIGHT © ABCELLERA

14

ABCL635 Science

NK3R antagonists are effective, non-hormonal options for VMS

Corporate Overview

Treatment

COPYRIGHT © ABCELLERA

15 Proposed mechanism of action for ABCL635 based on AbCellera clinical data and published literature.

ABCL635 Differentiation

Recently approved NK3R therapies are building the market

Fezolinetant

Corporate Overview

Small molecule NK3R antagonist

Elinzanetant

Small molecule NK3R and NK1R antagonist

Stage

Approved by US FDA on May 12, 2023

Stage

Approved by US FDA October 24, 2025

Dosing

Daily oral treatment

Dosing

Daily oral treatment

  • Effective in reducing severity and frequency of VMS.

    COPYRIGHT © ABCELLERA

  • Boxed warning for liver toxicity. Requires liver monitoring.

  • Effective in reducing severity and frequency of VMS.

  • Warnings for CNS depressant effect, daytime impairment, and liver enzyme elevation. Requires liver monitoring.

CNS: Central nervous system

16

ABCL635 Development

ABCL635 Phase 1 data supported advancing to Phase 2

SAFETY/TOLERABILITY ENDPOINT PHARMACOKINETIC ENDPOINT PHARMACODYNAMIC ENDPOINT

Corporate Overview

Favorable tolerability profile with no observed liver toxicity

All doses tested generally well tolerated

PK profile supports once monthly subcutaneous dosing

Estimated half-life of ~24 days

Biomarker data suggests strong and sustained engagement of NK3R

Demonstrated suppression of testosterone, LH, and FSH

ABCL635 PHASE 2 DOSE SELECTION

COPYRIGHT © ABCELLERA

A 600 mg SC dose administered once best approximates 300 mg SC at steady state*

and is being evaluated in the Phase 2 study

SC: subcutaneous.

  1. * Based on a comparison of predicted Cmax at steady state of a 300 mg dose once every 4 weeks, vs. the Cmax from a single dose of 600 mg.

    ABCL635 Differentiation

    Phase 2 data at week 4 suggest ABCL635 has the potential to be a first-in-class non-hormonal treatment for moderate and severe VMS

    Corporate Overview

    Markedly improved efficacy data compared to available

    non-hormonal therapies

    Data supports an improved safety profile with reduced liver and gastrointestinal findings

    Dosing convenience with long-acting subcutaneous

    self-injection

    COPYRIGHT © ABCELLERA

    DISCLAIMER: Information provided above is for illustrative purposes only and no head-to-head clinical trials have been conducted. Differences exist between study or trial designs and subject characteristics, and caution should be

  2. exercised when comparing data across trials.

ABCL635 Phase 2 Top-line Data

at Week 4

19

COPYRIGHT © ABCELLERA Corporate Overview

ABCL635 Phase 2 is a randomized, double-blind,

placebo-controlled, multicenter trial in postmenopausal women

Participants

Corporate Overview

Key inclusion criteria Endpoints

Efficacy analysis population/ Primary analysis methodology

Phase 2 Study Trial Design

N ~ 80 planned

92 postmenopausal women with moderate-to-severe VMS

N=46 per cohort

Comparable to Phase 3 entry criteria for approved NK3R small molecules Age 40-75 years

VMS frequency, VMS severity, patient-reported outcome measures, safety, pharmacokinetics Intent to treat population at 4 weeks

MMRM analyses except for patient global impression of change (Mann-Whitney U test)

Placebo-controlled treatment period Optional open-label extension (OLE)

Open-Label Extension 600 mg SC

ABCL635 600 mg SC

(N=46)

Screening

Study design

COPYRIGHT © ABCELLERA

R

Placebo

(N=46)

20 NK3R: Neurokinin 3 Receptor; MMRM: Mixed Models for Repeated Measures; SC: subcutaneous. Clinicaltrials.gov ID: NCT07118891.

Attention: This is an excerpt of the original content. To continue reading it, access the original document here.

AbCellera Biologics Inc. on 6ix

In the deck

Earlier from AbCellera Biologics

All AbCellera Biologics news releases